Insight Molecular Diagnostics (IMDX) vs Myriad Genetics (MYGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Insight Molecular Diagnostics (IMDX) has outperformed Myriad Genetics (MYGN) over the past year, losing 10.9% versus a loss of 43.2%. Over five years, MYGN leads with a -86.8% price change compared with -95.2% for IMDX. Myriad Genetics is the larger company by market cap ($401.7 million vs $107.3 million), about 3.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMDX | MYGN |
|---|---|---|
| Share price | $3.28 | $4.20 |
| Market cap | $107.34M | $401.73M |
| 1-day change | -5.20% | -1.87% |
| YTD return | -56.27% | -30.41% |
| 1-year return | -10.87% | -43.16% |
| 5-year return | -95.18% | -86.77% |
| EPS (TTM) | $-1.44 | $-1.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.51 | $8.59 |
| 52-week low | $2.42 | $2.74 |
| Distance from 52-week high | -61.46% | -51.11% |
| Analyst consensus | none | hold |
| Avg. price target upside | +151.52% | -6.90% |
| Average volume | 232.87K | 2.02M |
| Shares outstanding | 32.72M | 95.65M |
| Employees | 55 | 2,700 |
| Sector | Healthcare | Health Care |
| Industry | Diagnostics & Research | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Myriad Genetics is about 3.7 times larger than Insight Molecular Diagnostics by market value ($401.73M vs $107.34M).
- IMDX has outperformed MYGN by 32.3 percentage points over the past year.
- The two companies sit in different sectors: Insight Molecular Diagnostics in Healthcare and Myriad Genetics in Health Care.
About Insight Molecular Diagnostics
IMDX stock →Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally.
Healthcare · Diagnostics & Research · 55 employees
About Myriad Genetics
MYGN stock →Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,700 employees
IMDX vs MYGN FAQ
Which is bigger, Insight Molecular Diagnostics or Myriad Genetics?
Myriad Genetics (MYGN) is larger, with a market capitalization of $401.73M compared with $107.34M for Insight Molecular Diagnostics (IMDX).
Which stock has performed better over the past year, IMDX or MYGN?
IMDX returned -10.87% over the past 12 months, compared with -43.16% for MYGN (price return, excluding dividends). Past performance does not predict future results.
Are Insight Molecular Diagnostics and Myriad Genetics in the same industry?
No. Insight Molecular Diagnostics is in the Healthcare sector, while Myriad Genetics is in Health Care.